Refractory Glaucoma Treatment Market Widespread Research and Fundamental study to 2026

Refractory Glaucoma Treatment Market Growing
at Steady CAGR to 2026
Refractory Glaucoma Treatment Market - Global Industry Insights, Trends,
Outlook, and Opportunity Analysis, 2018-2026
Globally, Glaucoma is on rise. According to the Glaucoma research Foundation, Glaucoma is the
leading cause of irreversible blindness globally. Nearly 10% of the glaucoma patients who receive
proper treatment still experience a loss of vision. Around 64.3 million people were estimated to be
having glaucoma globally in 2013. Furthermore, according to the American Academy of
Ophthalmology, the current prevalence is high in Africa, and Latin America. Patients who fail to
respond to medications, undergo trabeculectomy surgery. However, few patients do not get completely
relieved from glaucoma even after trabeculectomy surgery. Therefore, novel treatment options are
required to be introduced for providing relief to such patients. Reducing intra-ocular pressure is the
most important long term medical need of refractory glaucoma patients.
Refractory Glaucoma Treatment Options
The global refractory glaucoma treatment market can be characterized based on the treatment options
and devices available in the market.
Ahmed Glaucoma Valve from New World Medical Inc., is a good treatment option available since 1993
for refractory glaucoma. This device also has applications in primary open angle glaucoma
unresponsive to medication, neovascular glaucoma, and congenital or infantile glaucoma. Various
studies have reflected the positive outcomes of using Ahmed Glaucoma Valve in refractory glaucoma
both in pediatrics and adults. Therefore, this device is in very high demand and usage globally.
Request For a Sample Copy of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/71
Alternate option like CyPass Micro-Stent from Transcend Medical showed impressive results in
patients with primary open-angle glaucoma. CyPass is a micro-invasive surgery which according to the
FDA guidelines needs to be performed in combination with cataract surgery. This is restricting the
wider acceptance among patients due to increased cost.
Clinical trials of Xen System showed positive results with 44% reduction in eye pressure and 65%
reduction in IOP medications in one year period. The Xen gel stent form Allergan reduces IOP with a
permanent implant that becomes flexible, allowing doctors to use IOP reduction therapies event after
the Xen implantation. Allergan received U.S. FDA approval for Xen Gel stent in November 2016. The
company plans to launch the Xen Gel stent in the U.S. market, for refractory glaucoma treatment, in
early 2017. The Xen system has already received CE mark and has distributed more than 10,500 stents
globally. Moreover, the new surgical system is also licensed for use in Canada, Switzerland, and
Turkey.
Future Market Dynamics
According to the American Academy of Ophthalmology, the global prevalence of glaucoma is
estimated to rise to 76 million in 2020 and 111.8 million in 2040. Rapidly aging population will be one
of the important factors for the increasing prevalence rate. There would be a disproportionate rise in the
prevalence in people residing in Asia and Africa. Slower adoption rate and high cost of the surgery is
limiting the market growth of refractory glaucoma treatment devices in emerging nations where
cataract surgery is the largely performed eye surgery. With new devices and technology being
introduced, there could be a strong wave of growth experienced in the North America and European
markets.
Iridex Corporation, a global provider of innovative laser systems, device and consumables in
ophthalmology announced at the European Glaucoma Society held in June 2016 about the positive
results of its MicroPulse P3 (MP3) device. The device powered with MicroPulse laser technology
showed long term benefits for patients with refractory glaucoma. Few detailed studies with successful
outcomes could lead global acceptance of this technology in future.
Glaucoma drainage devices are frequently used in refractory glaucoma to reduce the intra-ocular
pressure (IOC). These devices are available in either with IOP regulating valves or without it. Ahmed
glaucoma valve (AGV) is the most commonly used valve-based drainage device while Molteno,
Baerveldt, Shocket, and Eagle Vision implants are the non-valved drainage devices available in the
Refractory Glaucoma Treatment Market.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Globally, Glaucoma is on rise. According to the Glaucoma research Foundation, Glaucoma is the leading cause of irreversible blindness globally. Nearly 10% of the glaucoma patients who receive proper treatment still experience a loss of vision. Around 64.3 million people were estimated to be having glaucoma globally in 2013.

Download Report